These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35191018)

  • 1. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Navrazhina K; Frew JW; Grand D; Williams SC; Hur H; Gonzalez J; Garcet S; Krueger JG
    Br J Dermatol; 2022 Aug; 187(2):223-233. PubMed ID: 35191018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
    Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG
    J Am Acad Dermatol; 2020 Nov; 83(5):1341-1348. PubMed ID: 32416208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression.
    Navrazhina K; Garcet S; Zheng X; Hur HB; Frew JW; Krueger JG
    J Allergy Clin Immunol; 2022 Jan; 149(1):135-144.e12. PubMed ID: 34081946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Scheel CH; Rached NA; Gambichler T
    Br J Dermatol; 2022 Aug; 187(2):138-139. PubMed ID: 35531874
    [No Abstract]   [Full Text] [Related]  

  • 5. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.
    Navrazhina K; Garcet S; Frew JW; Zheng X; Coats I; Guttman-Yassky E; Krueger JG
    J Am Acad Dermatol; 2022 Feb; 86(2):322-330. PubMed ID: 34339761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa.
    Chu CB; Yang CC; Hsueh YY; Chen PC; Hong YK; Kuo YY; Tsai SJ
    Br J Dermatol; 2023 Nov; 189(6):719-729. PubMed ID: 37540988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa.
    Navrazhina K; Frew JW; Gilleaudeau P; Sullivan-Whalen M; Garcet S; Krueger JG
    J Allergy Clin Immunol; 2021 Jun; 147(6):2213-2224. PubMed ID: 33548397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
    Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
    J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.
    Thomi R; Yerly D; Yawalkar N; Simon D; Schlapbach C; Hunger RE
    Br J Dermatol; 2017 Nov; 177(5):1358-1366. PubMed ID: 28301691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
    Vossen ARJV; van der Zee HH; Davelaar N; Mus AMC; van Doorn MBA; Prens EP
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):761-765. PubMed ID: 30451329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
    Russell CB; Rand H; Bigler J; Kerkof K; Timour M; Bautista E; Krueger JG; Salinger DH; Welcher AA; Martin DA
    J Immunol; 2014 Apr; 192(8):3828-36. PubMed ID: 24646743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa.
    Kelly G; Hughes R; McGarry T; van den Born M; Adamzik K; Fitzgerald R; Lawlor C; Tobin AM; Sweeney CM; Kirby B
    Br J Dermatol; 2015 Dec; 173(6):1431-9. PubMed ID: 26282467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review.
    Vagnozzi E; Bruni M; Esposito M; Fargnoli MC
    J Dermatolog Treat; 2023 Dec; 34(1):2270091. PubMed ID: 37842732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
    Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
    Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes.
    Navrazhina K; Garcet S; Gonzalez J; Grand D; Frew JW; Krueger JG
    J Invest Dermatol; 2021 Sep; 141(9):2197-2207. PubMed ID: 33766512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
    Kimball AB; Loesche C; Prens EP; Bechara FG; Weisman J; Rozenberg I; Jarvis P; Peters T; Roth L; Wieczorek G; Kolbinger F; Jemec GBE
    Exp Dermatol; 2022 Oct; 31(10):1522-1532. PubMed ID: 35638561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa.
    Navrazhina K; Renert-Yuval Y; Frew JW; Grand D; Gonzalez J; Williams SC; Garcet S; Krueger JG
    Br J Dermatol; 2022 Apr; 186(4):684-693. PubMed ID: 34254293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice.
    Osorio-Gómez GF; Ortiz-Álvarez J; Diaz-Ceca D; Guijarro-Sánchez C; Conejo-Mir Sánchez J; Fernández Crehuet P
    Australas J Dermatol; 2024 May; 65(3):254-259. PubMed ID: 38597096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop.
    Hessam S; Sand M; Gambichler T; Skrygan M; Rüddel I; Bechara FG
    Br J Dermatol; 2018 Mar; 178(3):761-767. PubMed ID: 28975626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.